↓ Skip to main content

Cochrane Database of Systematic Reviews

Cyclophosphamide for multiple sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, January 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

blogs
1 blog
patent
1 patent
wikipedia
7 Wikipedia pages

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
115 Mendeley
Title
Cyclophosphamide for multiple sclerosis
Published in
Cochrane database of systematic reviews, January 2007
DOI 10.1002/14651858.cd002819.pub2
Pubmed ID
Authors

Loredana La Mantia, Clara Milanese, Nerina Mascoli, Roberto D'Amico, Bianca Weinstock‐Guttman

Abstract

Multiple sclerosis is a presumed cell-mediated autoimmune disease of the central nervous system. Cyclophosphamide (CFX) is a cytotoxic and immunosuppressive agent, used in systemic autoimmune diseases. Controversial results have been reported on its efficacy in MS. We conducted a systematic review of all relevant trials, evaluating the efficacy of CFX in patients with progressive MS.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 115 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 2%
Unknown 113 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 13%
Student > Master 13 11%
Student > Bachelor 13 11%
Student > Ph. D. Student 12 10%
Student > Postgraduate 9 8%
Other 28 24%
Unknown 25 22%
Readers by discipline Count As %
Medicine and Dentistry 45 39%
Nursing and Health Professions 8 7%
Neuroscience 7 6%
Agricultural and Biological Sciences 5 4%
Psychology 5 4%
Other 14 12%
Unknown 31 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2023.
All research outputs
#2,817,710
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#5,461
of 11,499 outputs
Outputs of similar age
#10,093
of 173,990 outputs
Outputs of similar age from Cochrane database of systematic reviews
#14
of 69 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,990 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.